Ogeda Seeks Financing After Successful Phase II For Non-Hormonal Menopause Drug
Executive Summary
Ogeda's non-hormonal menopause therapy, fezolinetant, has produced positive results in Phase II – an important step for the small Belgian biotech as it looks for partners or investment from further afield.
You may also be interested in...
GSK Spin-Out NeRRe Raises £23m For NK Antagonists
New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.